Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Mattel Inc (MAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Mattel Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Mattel Inc trades at $13.36 (market cap $3.87B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.3× Mattel Inc's market cap. Which is the better fit depends on your goals.
| ALNY | MAT | |
|---|---|---|
Market Cap | $39.89B | $3.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $22.16 |
52-Week Low | $278.09 | $13.05 |
Enterprise Value | $38.15B | $5.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MAT trades at $13.33, up 1.14% today, with a bearish technical signal from moving averages and oscillators showing neutral RSI levels. The company reported a net income of $397.58M in 2025, with a P/E of 8.54 and ROE of 23.56% indicating solid profitability. Recent news includes expansion of UNO Social Clubs and upcoming Q2 2026 earnings release on August 4, 2026.
The stock presents a mixed outlook: analyst consensus is a Buy with a $14.50 price target, but recent earnings misses and a negative net cash flow of -$145M in 2025 pose risks. Upside potential exists from brand expansions and Comic-Con product launches, while competitive pressures and debt levels of $2.33B require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
